Reviewer's report

**Title:** Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study

**Version:** 2  **Date:** 14 November 2014

**Reviewer:** Michiya Kobayashi

**Reviewer's report:**

This is a manuscript of a feasibility study of adjuvant chemotherapy with S-1 for Japanese breast cancer patients after PSC.

This issue is important and interesting for the readers of the journal.

However, there are several points to be revised for publication.

Major

1) Author mixed up S-1 alone, and S-1 with radiation and/or endocrine therapy. This strategy is comprehensive, however, author should evaluate the compliance and AE according to these 4 groups.

2) In the discussion section, several sentences are overlapped with those in the introduction section.

Minor

1) Author describes “S-1 is believed to have higher antitumor activity than UFT, with lower toxicity” in the introduction and discussion sections. However, this may cause the misunderstanding to the readers as lower toxicity then UFT.

2) In the result section, author described S-1 was concurrently administered with endocrine therapy and trastuzumab. However, this study was focused on S-1. Author should describe as endocrine and trastuzumab were concurrently administered.

3) In the result section, author described that 32 patients received radiotherapy. However, 31 patients received radiotherapy in table 1.

**Level of interest:** An article of limited interest

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.